title: [Relapse rate within 6 months after successful ECT: a naturalistic prospective peer- and self-assessment analysis].
abstract: BACKGROUND
  Up to 100% relapse rate after successful electroconvulsive therapy (ECT) poses a challenge for patients and psychiatrists. The aim of the study was to evaluate the outcome of patients affected by major depression after the successful course of acute ECT.
  
  
  METHODS
  84 patients recruited in a randomized double blind multicenter study designed to investigate the optimal stimulation placement in acute ECT had a follow up under naturalistic conditions between the 5th and 7th month. Outcome, maintenance therapy and patients; attitude were evaluated with semi structured questionnaires by patients and the study raters.
  
  
  RESULTS
  82.14% (68/84) questionnaires of the patients and 83.3% (70/84) of the rater were returned. 98% of the patients had at least one antidepressant; only in 23% (20/68) lithium was prescribed. 35% (7/20) of the patients with lithium and 57% (16/28) without lithium had a relapse within the first 6 months (OR 0.6) in a median of 2.5 months. Only one institution offered maintenance ECT in 8.3% (7/84) patients. For 52.2% of the patients ECT was a helpful treatment an 49.3% would recommend the therapy to their relatives. The vast majority (59.4%) wishes a better information about the ECT and 21.4% feel frightening about the therapy.
  
  
  CONCLUSIONS
  The results show a high relapse rate and highlight the meaning of maintenance medication especially for a lithium combination therapy, as stated before. In regard to the subjective sensation the patients claim a better education about the ECT and anyway one of four patients feel frightening about the therapy.
authors.affiliation: Landesklinik Rankweil. gerald@rehor.at.
authors.forename: G
authors.initials: G
authors.lastname: Rehor
authors.forename: A
authors.initials: A
authors.lastname: Conca
authors.forename: W
authors.initials: W
authors.lastname: Schlotter
authors.forename: R
authors.initials: R
authors.lastname: Vonthein
authors.forename: S
authors.initials: S
authors.lastname: Bork
authors.forename: R
authors.initials: R
authors.lastname: Bode
authors.forename: M
authors.initials: M
authors.lastname: Hüll
authors.forename: C
authors.initials: C
authors.lastname: Plewnia
authors.forename: J
authors.initials: J
authors.lastname: Di Pauli
authors.forename: M
authors.initials: M
authors.lastname: Prapotnik
authors.forename: O
authors.initials: O
authors.lastname: Peters
authors.forename: J
authors.initials: J
authors.lastname: Peters
authors.forename: G W
authors.initials: GW
authors.lastname: Eschweiler
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000628:therapy*; D004311:Double-Blind Method; D004565:Electroconvulsive Therapy / Q000009:adverse effects / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016651:Lithium Carbonate / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010359:Patient Readmission; D017060:Patient Satisfaction; D012008:Recurrence; D019233:Retreatment
chemical_list: D000928:Antidepressive Agents; D016651:Lithium Carbonate